The Effect of Theta-burst Stimulation on Serum BDNF

Last updated: May 2, 2023
Sponsor: Taipei City Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gambling Problems

Treatment

Theta Burst Stimulation

Clinical Study ID

NCT05854706
TCHIRB-11003020
  • Ages 20-65
  • All Genders

Study Summary

The goal of this clinical trial is to investigate the effect of theta burst stimulation for depression and serum brain-derived neurotrophic factor (BDNF) in individuals with major depression. The main question it aims to answer is whether 10 sessions of theta burst stimulation can influence the serum level of BDNF.

Participants will be randomized into active group and sham group. Researchers will compare the level of BDNF in these groups.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. age between 20 and 65 years;
  2. fulfilling the Diagnostic and Statistical Manual version 5 (DSM-5) criteria of Majordepressive disorder assessed by the Structured Clinical Interview

Exclusion

Exclusion Criteria:

  1. Inability to provide informed consent or comprehend the study procedure;
  2. A major psychiatric illness including schizophrenia spectrum disorder, bipolarspectrum disorder, and major depressive disorder with psychotic features.
  3. A current DSM-5 diagnosis of substance use disorder except nicotine use disorder orthe use of one to two low-potency benzodiazepine tablets for sleep impairment;
  4. Have known preexisting noise-induced hearing loss, concurrent treatment with ototoxicmedications, or with cochlear implants.
  5. Unstable medical illness, including malignancy, uncontrolled diabetes mellitus,unstable cardiac disease or recent myocardial infarction, or cerebrovascular orcardiovascular risk factors that require intensive medical management
  6. On medications known to lower seizure threshold (e.g., TCA, bupropion, clozapine)
  7. Implants controlled by physiological signals, including pacemaker, implantablecardioverter defibrillator, cochlear implant.
  8. Metallic objects in the head, including stenting, suture.
  9. Elevated risk of seizure due to traumatic brain history, seizure history, and headtrauma, intracranial lesion, and alcohol or benzodiazepines withdrawal syndrome,stimulant intoxication.

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: Theta Burst Stimulation
Phase:
Study Start date:
April 17, 2023
Estimated Completion Date:
June 30, 2026

Study Description

There is an increasing evidence that the BDNF could be involved in the mode of action of antidepressants and, perhaps, of brain stimulation. Brain stimulation methods, such as electroconvulsive therapy (ECT) has been used to treat patients with severe depression and is reported to increase BDNF levels in blood. Numerous studies has demonstrated that repetitive transcranial magnetic stimulation (rTMS) as an alternative to ECT, produced the most robust antidepressant effects, and is the most widely applied treatment protocol for major depressive disorder (MDD). Theta-burst stimulation (TBS) is a novel form of rTMS, and has recently emerged as a method with the potential to produce similar anti-depressant effects much more rapidly than traditional repetitive TMS protocols. It is presumed that BDNF mediates the therapeutic benefits of brain rTMS, but previous results are contradictory.

Specific Aims:

The study is a four-week randomized, double-blind, sham-controlled study comparing pre- and post-treatment serum BDNF levels of patients with MDD, who receive active or sham of prolonged intermittent TBS (piTBS) treatment.

Method:

During the four-week double-blind phase of active or sham piTBS treatment, piTBS sessions are scheduled daily in a 5-day sequence for 10 sessions over two weeks. Symptomatic ratings and serum BDNF measurement are administered at baseline (W0, before brain stimulation), at the end of Week 2 brain stimulation treatments, and at the two-week follow-up after the treatment (Week 4). Otherwise, the symptomatic changes are also evaluated at the end of Week 1 brain stimulation. The study include sixty patients with major depression and all participants are randomly allocated (1:1) to groups receiving either active or sham piTBS group. The aim of the present study is to explore the effect of piTBS therapy on serum BDNF levels and change of depression symptom rating scale, as well as their associations in patients with MDD.

Connect with a study center

  • Taipei City Hospital

    Taipei, Taipei CITY 105
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.